Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.


Clinical Trial Description

The primary objective of this clinical investigation is to compare the difference in change in retinal blood vessel density (peripapillary and macular) between latanoprostene bunod (LBN) ophthalmic solution 0.024% dosed once daily (QD) and timolol maleate 0.5% dosed twice daily (BID) in subjects with OAG or OHT and in normal subjects. Primary Efficacy Endpoint The primary efficacy endpoint for this study is the change in retinal blood vessel density (peripapillary and macular) between treatment groups after 4 weeks of treatment (Visit 4 [Week 5] and Visit 6 [Week 11]). Secondary Efficacy Endpoints The secondary efficacy endpoint for this study is change in best-corrected visual acuity (BCVA). Safety Endpoints The safety endpoint for this study is the incidence of ocular and systemic adverse events (AEs). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03931317
Study type Interventional
Source University of California, San Diego
Contact
Status Completed
Phase N/A
Start date December 3, 2018
Completion date March 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04412096 - Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance Phase 4
Completed NCT04888156 - Impact of Self-tonometry on Glaucoma Treatment Decision.
Withdrawn NCT04064918 - Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity N/A